Janumet XR® Extended-Release Tablets for Type 2 Diabetes

What Janumet XR® Is and How It Works

Janumet XR combines sitagliptin, a DPP-4 inhibitor, with metformin extended release in a single tablet. It helps adults with type 2 diabetes improve blood sugar control alongside diet and exercise. Common strengths include 50/500 mg, 50/1000 mg, and 100/1000 mg. Many patients receive once-daily dosing with the evening meal. Janumet XR targets both fasting and after-meal glucose. CanadianInsulin is a prescription referral service. Prescriptions are verified with your clinic, and orders are filled by licensed Canadian pharmacies.

Sitagliptin increases incretin hormone levels by inhibiting DPP-4. This boosts glucose-dependent insulin release and reduces glucagon. Metformin XR decreases hepatic glucose production and improves insulin sensitivity. Together, the combination supports A1C reduction without significant weight gain. The extended-release layer helps improve gastrointestinal tolerability. People often ask about Janumet XR 50/1000 uses and Janumet XR 100 mg/1000 mg uses; both strengths serve the same indication and differ mainly in dose selection.

Dosage and Usage

• Take Janumet XR exactly as prescribed, usually once daily with a meal. Many start with a lower metformin XR dose, then increase as tolerated.
• Common strengths include 50/500 mg, 50/1000 mg, and 100/1000 mg tablets. The total daily sitagliptin dose should not exceed 100 mg.
• Janumet XR 100 mg/1000 mg dosage may suit patients already on sitagliptin 100 mg and metformin 1000 mg, if tolerated.
• Swallow tablets whole. Do not crush, split, or chew. The XR matrix may leave a soft shell in stool.
• If you miss a dose, take it with the next scheduled meal. If it is near time for the next dose, skip the missed tablet. Do not double up.
• Take with food to reduce stomach upset. Titrate metformin XR gradually to improve tolerability.
• Renal function influences dose selection. Sitagliptin exposure rises with reduced kidney function. The product may not be appropriate in severe impairment.
• Hold metformin-containing therapy before certain iodinated contrast procedures and during acute illness that increases dehydration risk.

• Store tablets at 20–25°C (68–77°F). Short excursions 15–30°C (59–86°F) are acceptable.
• Keep tablets dry and in the original, tightly closed bottle.
• When you travel, carry your medication in hand luggage, away from heat and moisture.
• Bring a copy of your prescription and keep doses in a daily organizer if helpful.
• Do not store in a bathroom or a car glove compartment.

Benefits and Savings

Janumet XR reduces A1C by combining two complementary mechanisms. The DPP-4 component targets postprandial spikes. Metformin XR addresses fasting glucose and hepatic output. Many patients see improved A1C with low risk of hypoglycemia when not combined with insulin or a sulfonylurea. The regimen is weight neutral for most, and metformin may support modest weight stability.

The extended-release design allows once-daily dosing for convenience. Fixed-dose combination tablets may simplify routines and reduce pill burden. Many customers save 60–80% vs typical U.S. prices. See our promotions page for current offers, including any janumet xr coupon if available.

Side Effects and Safety

• Common effects: nausea, diarrhea, gas, stomach discomfort, and indigestion, especially during dose titration.
• Other effects: headache, upper respiratory symptoms, fatigue, and mild taste changes.
• Metformin-related: reduced vitamin B12 levels with long-term use; periodic monitoring may be appropriate.
• Skin: rash or itching can occur; discontinue for severe reactions.
• Musculoskeletal: joint pain has been reported with DPP-4 inhibitors.

Serious risks are rare but include lactic acidosis from the metformin component, which is a medical emergency. Pancreatitis has been reported with DPP-4 inhibitors; stop therapy if suspected. Severe joint pain and bullous pemphigoid have also occurred. Do not use in patients with eGFR below 30 mL/min/1.73 m² or in acute metabolic acidosis. Hypoglycemia risk increases when combined with insulin or sulfonylureas; dose reductions of those agents may be needed. Assess hepatic disease, alcohol use, and conditions that increase dehydration before therapy.

Onset Time

Some glucose improvements may appear within the first week as metformin XR titration begins and sitagliptin starts working. Gastrointestinal tolerability often improves after several days. A1C reductions become clearer over 8–12 weeks as dosing stabilizes and lifestyle measures continue. Weight effects are generally neutral over time.

Compare With Alternatives

Several alternatives may fit different goals or preferences. Trulicity® (dulaglutide) is a once-weekly GLP-1 receptor agonist injection. It can lower A1C more than many oral agents and often supports weight loss. Gastrointestinal effects are more common at initiation. Rybelsus® (semaglutide) is an oral GLP-1 option taken daily before food, offering greater A1C and weight effects than DPP-4 inhibitors for many patients.

Mounjaro® (tirzepatide) is a once-weekly GIP/GLP-1 agent that can deliver robust A1C and weight reductions. It is an injection and requires titration to improve tolerability. For those considering a daily GLP-1 injection, see Victoza Pens for another branded option in this class. These agents differ in route, weight effects, and contraindications. Choice depends on individual goals, tolerability, and coverage.

Combination Therapy

• With SGLT2 inhibitors: Often paired to target fasting and postprandial glucose while supporting cardio-renal outcomes.
• With basal insulin: Consider lowering insulin dose to reduce hypoglycemia risk; monitor glucose closely during changes.
• With sulfonylureas: Reduced sulfonylurea doses may be needed to avoid low blood sugar.
• With statins and antihypertensives: Common in cardiometabolic care; monitor for interactions and kidney function.
• Avoid duplication with other DPP-4 inhibitors or fixed-dose sitagliptin combinations.

Patient Suitability and Cost-Saving Tips

Janumet XR suits adults with type 2 diabetes who need additional control beyond lifestyle measures. It is not for type 1 diabetes or diabetic ketoacidosis. It is generally weight neutral and has a low hypoglycemia risk when not combined with insulin secretagogues. Kidney function should be adequate; avoid use at eGFR below 30 mL/min/1.73 m².

Use caution in hepatic impairment, heavy alcohol use, dehydration, or conditions that increase lactic acidosis risk. History of pancreatitis, severe skin reactions, or hypersensitivity to sitagliptin or metformin may preclude use. Pregnancy and breastfeeding require individualized assessment.

To manage costs, consider ordering a multi-month supply if appropriate and permitted by your prescription. Reorder before running low to avoid gaps. CanadianInsulin partners with licensed and vetted pharmacies to supply authentic brand medications with value-focused pricing and a broad selection.

Authoritative Sources

Merck US Prescribing Information for Janumet XR

FDA Medication Guide and Labeling

Health Canada Drug Product Database: Janumet XR

Order Janumet XR® from CanadianInsulin: add to cart, upload your prescription, and we ship with prompt, express, cold-chain handling.

This page is educational and does not replace professional medical advice. Always speak with a qualified healthcare provider about diagnosis, treatment, and medication choices.